The Effects of Maxipost (BMS 204352) on Cerebral Hemodynamic and Headache in Healthy Volunteers and Migraine Patients

• Status: Completed
• Trial end date: 2020-02-29
• Target enrollment: 0
• Participant gender: All

Summary

It is not previously investigated whether, there is a correlation between potassium channels and migraine, so it is unclear whether, this signaling pathway through potassium channels has an impact on migraine pathophysiology.

Maxipost (BMS 204352) is a vasoactive molecule that causes vasodilation via the big calcium dependent potassium (BKCa) channel signaling pathway. Maxipost decreases the blood pressure and maxipost infusion causes headache in healthy volunteers. A possible coherence between maxipost and headache/migraine in healthy volunteers and migraine patients is yet to be investigated.

The present study aims to clarify a possible coherence between maxipost and headache/migraine and it will help to shed light on the importance of potassium channels in migraine. In general, the study will contribute to a greater understanding of migraine pathogenesis and possibly lead to development of specific migraine treatment.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Danish Headache Center

Criteria

Inclusion Criteria:

• Migraine patients without aura who fulfill criteria in the international classification of headaches. This does not apply to healthy volunteers.

• 18-60 years.

• 50-90 kg.

• Women of childbearing potential must use adequate contraception.

Exclusion Criteria:

• Headache less than 48 hours before the tests start

• All primary headaches, except migraine without aura for migraine patients, according to international classification of headache

• Daily consumption of drugs of any kind other than oral contraceptives

• Pregnant or nursing women.

• Cardiovascular disease of any kind, including cerebrovascular diseases.